|
|
The Body Covers: The 6th International Congress on Drug Therapy in HIV Infection
Complete Index
November 17, 2002
November 18, 2002
- Antiretroviral Treatment Regimens Suitable for Resource-Poor Settings
Coverage by Mark A. Wainberg, Ph.D.
- New Treatments and Targets
Coverage by Mark A. Wainberg, Ph.D.
- Review of Case Studies With Audience and Panel Participation
Coverage by Simon D. Portsmouth, M.B.Ch.B., M.R.C.P., Dip.G.U.M., D.F.F.P.
- Treatment Interruptions
Coverage by Simon D. Portsmouth, M.B.Ch.B., M.R.C.P., Dip.G.U.M., D.F.F.P.
- What to Start With and What to Include? Should Compounds With Non Cross-Resistance Profiles Be Preferentially Used in Initial or Late Therapy?
Coverage by Simon D. Portsmouth, M.B.Ch.B., M.R.C.P., Dip.G.U.M., D.F.F.P.
November 19, 2002
November 20, 2002
November 21, 2002
- Comparison of the Efficacy and Safety of Tenofovir Versus d4T When Used in Combination With 3TC and Efavirenz in HIV-Infected Patients Naive to Antiretroviral Therapy After 48 Weeks of Treatment (Study 903)
Coverage by Mark Nelson, M.A., M.B.B.S., M.R.C.P.
- The Development of K65R Versus Thymidine Analogue-Associated Mutations in Antiviral-Treated Patients
Coverage by Mark Nelson, M.A., M.B.B.S., M.R.C.P.
- Efficacy and Safety of GW433908/Ritonavir Once Daily in Therapy-Naive Subjects, 48-Week Results -- The SOLO Study
Coverage by Mark A. Wainberg, Ph.D.
- Efficacy and Safety of Trizivir Maintenance Treatment After First-Line Quadruple Induction Therapy; Interim 24-Week Data From AZLF3004/TRISUD
Coverage by Mark A. Wainberg, Ph.D.
- Efficacy of Quad Therapy in Antiretroviral-Naive Adults With Very Low CD4 Cell Counts: The Tetra Study
Coverage by Mark A. Wainberg, Ph.D.
- Genotypic and Phenotypic Characterization of Virologic Failure Through 48 Weeks Among Treatment-Naive Patients Taking Tenofovir or d4T in Combination With 3TC and Efavirenz
Coverage by Mark Nelson, M.A., M.B.B.S., M.R.C.P.
- Immune Reconstitution Is Similar in Antiretroviral-Naive Subjects Following 1 Year of Therapy With a Triple NRTI-Based or Protease Inhibitor-Containing ARV Regimen
Coverage by Mark A. Wainberg, Ph.D.
- Pharmacokinetics Following Single Doses Administrations of Tenofovir in Subjects With Renal Impairment
Coverage by Mark Nelson, M.A., M.B.B.S., M.R.C.P.
- A Population Based-Analysis of Amprenavir Trough Concentrations Assessed in the Course of Therapeutic Drug Monitoring
Coverage by Mark A. Wainberg, Ph.D.
- Safety Profile of Tenofovir in Treatment-Experienced Patients From Randomized, Placebo-Controlled Clinical Trials
Coverage by Mark Nelson, M.A., M.B.B.S., M.R.C.P.
- Tenofovir and ddI EC: Investigation of Pharmacokinetic Drug-Drug and Drug-Food Interactions
Coverage by Mark Nelson, M.A., M.B.B.S., M.R.C.P.
|
Advertisement
|
